Chronic Kidney Disease
📧 Sign up to get email alerts when something new happens for Chronic Kidney Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: The ILERVAS Project: Assessing the Prevalence of Subclinical Vascular Disease and Hidden Kidney Disease [NA]
Clinical trial registry update for the ILERVAS Project assessing the prevalence of subclinical vascular disease and hidden kidney disease, s…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) [Phase 3]
Phase 3 trial evaluating the efficacy, safety, and tolerability of Zibotentan in combination with Dapagliflozin versus Dapagliflozin alone i…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Transforming Hemodialysis-Related Vascular Access Education [NA]
An ongoing clinical trial at the University of Pennsylvania is testing a program to improve education about hemodialysis vascular access; re…
-
CLINICAL_TRIALS withdrawal · 2026-03-25Clinical Trial Update: Serum Potassium Prediction Using Machine Learning and Single-lead ECG
A Brigham and Women's Hospital clinical trial evaluating potassium prediction from machine learning and a single-lead ECG has been withdrawn…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Multimedia Health Education on Physical Fitness and Physical Activity for Patients With Chronic Kidney Disease [NA]
A clinical trial update indicates recruitment is ongoing for a study evaluating multimedia health education on physical fitness and physical…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-24EMA Authorised: Vafseo (vadadustat) — Medice Arzneimittel Pütter GmbH & Co. KG
The EMA authorised vadadustat (brand Vafseo) for the treatment of anemia associated with chronic kidney disease in the EU.
-
EMA approval · 2026-03-24EMA Authorised: Jardiance (empagliflozin) — Boehringer Ingelheim International GmbH
EMA authorised Jardiance (empagliflozin) in the European Union for type 2 diabetes mellitus, heart failure, and chronic kidney disease, unde…
-
EMA approval · 2026-03-24EMA Authorised: Velphoro (sucroferric oxyhydroxide) — Vifor Fresenius Medical Care Renal Pharma France
The EMA authorized Velphoro (sucroferric oxyhydroxide) for the treatment of hyperphosphatemia in patients with chronic kidney disease on ren…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease [Phase 3]
Phase 3 clinical trial update evaluating sotagliflozin to slow kidney function decline in adults with Type 1 diabetes and diabetic kidney di…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Monitoring of the Sympathetic/Vagal Balance Through Multiparametric Analysis of Heart Rate Variability (HRV)
A clinical trial update describes a prospective study using multiparametric heart rate variability analysis to monitor autonomic balance in …
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Expanded Hemodialysis Versus High-Volume Online Hemodiafiltration for Uremic Toxin Removal [NA]
This clinical trial compares expanded hemodialysis to high-volume online hemodiafiltration for uremic toxin removal in patients with end-sta…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial [Phase 3]
The BRACKETS Phase 3 pilot trial is currently recruiting to test strategies for reducing bleeding in patients with chronic kidney disease or…
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease [Phase 3]
Phase 3 trial evaluating low-dose rivaroxaban for cardiovascular disease in patients with advanced chronic kidney disease has completed.
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease [Phase 3]
A Phase 3 trial called REACT is evaluating a treatment for adults with type 2 diabetes mellitus and chronic kidney disease, and the study is…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Improving Continuous Renal Replacement Therapy Outcomes in Neonates and Infants Through Interdisciplinary Collaboration
Clinical trial update describing an ongoing study to improve continuous renal replacement therapy outcomes in neonates and infants with kidn…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease [Phase 1]
Phase 1 trial assessing safety, tolerability, pharmacokinetics and pharmacodynamics of OJR520 in healthy volunteers and individuals with chr…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: Prediction of Hyperkalemia in Dialysis Patients Through Waveform Analysis Using Wearable ECG
This clinical trial update reports on predicting hyperkalemia in dialysis patients by analyzing wearable ECG waveform data and indicates the…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: Shared Decision Making in Dialysis [NA]
The University of Rochester-sponsored trial on shared decision making in dialysis has completed and posted its results on 2026-03-20.
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: Aspirin to Target Arterial Events in Chronic Kidney Disease [Phase 3]
A Phase 3 trial evaluating aspirin to reduce arterial events in chronic kidney disease has been terminated.
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
A clinical trial from University Hospital, Toulouse aims to predict development, progression, or complications of kidney, immune, and transp…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function [Phase 3]
Phase 3 clinical trial sponsored by AstraZeneca to evaluate the Balcinrenone and dapagliflozin combination in patients with heart failure an…
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients [Phase 4]
This clinical trial update describes a Phase 4 study evaluating neurocognitive function changes associated with extended-release tacrolimus …
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: A Prospecitve Multicenter, Observational Registry Study
AstraZeneca is sponsoring a prospective multicenter observational registry study on Chronic Kidney Disease, currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Multimodal Intervention for Early Chronic Kidney Disease in Young People: Dysbiosis and Inflammation (CKD) [NA]
A planned clinical trial will evaluate a multimodal intervention (exercise, diet, and symbiotic therapy) for early chronic kidney disease in…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus [Phase 2]
Clinical trial update on the safety and tolerability of difelikefalin in adolescents on haemodialysis with moderate-to-severe pruritus. The …